$6.03
0.183.08%
Last update: Nov 6, 4:00 PM
Alumis Inc (ALMS) Stock Price, Quote, News & History
ALMSNASDAQ
Alumis (ALMS) stock drops over 50% after Phase 2b lupus trial misses overall endpoints, but sub-group data shows promise.
You can purchase shares of Alumis (NASDAQ:ALMS) through any online brokerage.
Other companies in Alumis’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Alumis has a consensus price target of $30.70.
The stock price for Alumis (NASDAQ: ALMS) is $6.03 last updated November 6, 2026 at 4:00 PM EST.
There are no upcoming dividends for Alumis.
Alumis does not have any upcoming earnings scheduled.
There is no upcoming split for Alumis.
Alumis is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central...
